vs
Side-by-side financial comparison of Prime Medicine, Inc. (PRME) and TaoWeave, Inc. (TWAV). Click either name above to swap in a different company.
Prime Medicine, Inc. is the larger business by last-quarter revenue ($838.0K vs $622.0K, roughly 1.3× TaoWeave, Inc.). TaoWeave, Inc. runs the higher net margin — -448.2% vs -5498.7%, a 5050.5% gap on every dollar of revenue. On growth, TaoWeave, Inc. posted the faster year-over-year revenue change (10.5% vs -61.6%).
Prime Medicine, Inc. is an American biotechnology company developing gene therapies based on prime editing. The company is headquartered in Cambridge, Massachusetts.
PRME vs TWAV — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $838.0K | $622.0K |
| Net Profit | $-46.1M | $-2.8M |
| Gross Margin | — | 47.1% |
| Operating Margin | -5800.5% | -126.4% |
| Net Margin | -5498.7% | -448.2% |
| Revenue YoY | -61.6% | 10.5% |
| Net Profit YoY | -9.0% | -215.4% |
| EPS (diluted) | $-0.22 | — |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $838.0K | $622.0K | ||
| Q3 25 | $1.2M | $601.0K | ||
| Q2 25 | $1.1M | $592.0K | ||
| Q1 25 | $1.5M | $622.0K | ||
| Q4 24 | $2.2M | $563.0K | ||
| Q3 24 | — | $578.0K | ||
| Q2 24 | $0 | $611.0K | ||
| Q1 24 | $591.0K | $626.0K |
| Q4 25 | $-46.1M | $-2.8M | ||
| Q3 25 | $-50.6M | $-2.3M | ||
| Q2 25 | $-52.6M | $-605.0K | ||
| Q1 25 | $-51.9M | $-672.0K | ||
| Q4 24 | $-42.3M | $-884.0K | ||
| Q3 24 | — | $-1.0M | ||
| Q2 24 | $-55.3M | $-983.0K | ||
| Q1 24 | $-45.8M | $-1.1M |
| Q4 25 | — | 47.1% | ||
| Q3 25 | — | 40.6% | ||
| Q2 25 | — | 38.5% | ||
| Q1 25 | — | 40.0% | ||
| Q4 24 | — | 24.0% | ||
| Q3 24 | — | 13.7% | ||
| Q2 24 | — | 19.6% | ||
| Q1 24 | — | -0.5% |
| Q4 25 | -5800.5% | -126.4% | ||
| Q3 25 | -4406.0% | -133.4% | ||
| Q2 25 | -4787.2% | -115.4% | ||
| Q1 25 | -3603.3% | -111.1% | ||
| Q4 24 | -2025.7% | -164.8% | ||
| Q3 24 | — | -185.5% | ||
| Q2 24 | — | -166.6% | ||
| Q1 24 | -8179.5% | -189.1% |
| Q4 25 | -5498.7% | -448.2% | ||
| Q3 25 | -4129.1% | -381.0% | ||
| Q2 25 | -4716.7% | -102.2% | ||
| Q1 25 | -3568.8% | -108.0% | ||
| Q4 24 | -1936.6% | -157.0% | ||
| Q3 24 | — | -179.9% | ||
| Q2 24 | — | -160.9% | ||
| Q1 24 | -7743.0% | -181.5% |
| Q4 25 | $-0.22 | — | ||
| Q3 25 | $-0.32 | — | ||
| Q2 25 | $-0.41 | — | ||
| Q1 25 | $-0.40 | — | ||
| Q4 24 | $-0.31 | — | ||
| Q3 24 | — | — | ||
| Q2 24 | $-0.46 | — | ||
| Q1 24 | $-0.44 | $-0.07 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $63.0M | $2.3M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $120.9M | $7.0M |
| Total Assets | $342.7M | $8.2M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $63.0M | $2.3M | ||
| Q3 25 | $71.4M | $3.7M | ||
| Q2 25 | $53.8M | $10.8M | ||
| Q1 25 | $91.9M | $4.3M | ||
| Q4 24 | $182.5M | $5.0M | ||
| Q3 24 | — | $5.6M | ||
| Q2 24 | $55.6M | $5.9M | ||
| Q1 24 | $94.2M | — |
| Q4 25 | $120.9M | $7.0M | ||
| Q3 25 | $161.8M | $9.8M | ||
| Q2 25 | $60.9M | $11.3M | ||
| Q1 25 | $106.9M | $3.4M | ||
| Q4 24 | $153.1M | $4.0M | ||
| Q3 24 | — | $4.7M | ||
| Q2 24 | $196.6M | $5.1M | ||
| Q1 24 | $243.8M | $4.4M |
| Q4 25 | $342.7M | $8.2M | ||
| Q3 25 | $385.0M | $10.9M | ||
| Q2 25 | $279.0M | $13.1M | ||
| Q1 25 | $328.2M | $4.8M | ||
| Q4 24 | $297.5M | $5.3M | ||
| Q3 24 | — | $6.0M | ||
| Q2 24 | $259.7M | $6.3M | ||
| Q1 24 | $311.4M | $5.9M |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-37.3M | $-744.0K |
| Free Cash FlowOCF − Capex | $-37.5M | — |
| FCF MarginFCF / Revenue | -4480.4% | — |
| Capex IntensityCapex / Revenue | 34.6% | — |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | $-167.1M | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-37.3M | $-744.0K | ||
| Q3 25 | $-35.0M | $-1.6M | ||
| Q2 25 | $-41.4M | $-37.0K | ||
| Q1 25 | $-48.9M | $-680.0K | ||
| Q4 24 | $16.2M | $-255.0K | ||
| Q3 24 | — | $-911.0K | ||
| Q2 24 | $-45.5M | $-1.6M | ||
| Q1 24 | $-67.7M | $-630.0K |
| Q4 25 | $-37.5M | — | ||
| Q3 25 | $-35.3M | — | ||
| Q2 25 | $-43.0M | — | ||
| Q1 25 | $-51.3M | — | ||
| Q4 24 | $14.5M | — | ||
| Q3 24 | — | — | ||
| Q2 24 | $-47.4M | — | ||
| Q1 24 | $-70.0M | — |
| Q4 25 | -4480.4% | — | ||
| Q3 25 | -2880.5% | — | ||
| Q2 25 | -3855.1% | — | ||
| Q1 25 | -3526.8% | — | ||
| Q4 24 | 662.1% | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | -11849.6% | — |
| Q4 25 | 34.6% | — | ||
| Q3 25 | 20.2% | — | ||
| Q2 25 | 141.0% | — | ||
| Q1 25 | 166.6% | — | ||
| Q4 24 | 82.0% | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | 393.2% | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
